| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| GRI Bio, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 43.3K | $29.7K | $0.69 | Jan 23, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| GRI | GRI Bio, Inc. | Jan 23, 2025 | 1 | $29.7K | 4 | Jan 24, 2025 | Chief Financial Officer |
| WINT | WINDTREE THERAPEUTICS INC /DE/ | Jan 8, 2025 | 0 | $0 | 3 | Jan 14, 2025 | Director |
| GRI | GRI BIO, Inc. | Sep 22, 2023 | 1 | $127K | 4 | Sep 26, 2023 | Chief Financial Officer |
| GRI | Vallon Pharmaceuticals, Inc. | Feb 15, 2022 | 1 | $282K | 4 | Mar 1, 2022 | Chief Financial Officer |
| GRI | Vallon Pharmaceuticals, Inc. | Jun 2, 2021 | 3 | $25.2K | 4 | Jun 4, 2021 | Chief Financial Officer |
| GRI | Vallon Pharmaceuticals, Inc. | May 14, 2021 | 1 | $0 | 4 | May 18, 2021 | Chief Financial Officer |
| GRI | Vallon Pharmaceuticals, Inc. | May 11, 2021 | 0 | $0 | 3 | May 18, 2021 | Chief Financial Officer |